BioSyent (CVE:RX) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

BioSyent Inc. (CVE:RX) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of C$10.89 and traded as high as C$11.15. BioSyent shares last traded at C$11.05, with a volume of 8,284 shares.

BioSyent Stock Down 0.2 %

The company has a market cap of C$128.07 million, a P/E ratio of 18.42 and a beta of 0.93. The business’s 50 day moving average price is C$11.32 and its 200-day moving average price is C$10.89. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91.

Insiders Place Their Bets

In other BioSyent news, insider FAX Capital Corp. sold 112,400 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total transaction of C$1,267,557.28. Also, Senior Officer Robert Joseph March sold 4,775 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Over the last quarter, insiders have sold 349,144 shares of company stock valued at $3,903,370. 33.65% of the stock is currently owned by corporate insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.